SAREPTA THERAPEUTICS, INC. Selling, General and Administrative Expense
SAREPTA THERAPEUTICS, INC. (SRPT) reported Selling, General and Administrative Expense of $107.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $107.60M, a 21.97% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $108.95M, a 18.47% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $128.30M, a 21.71% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $91.89M, a 28.32% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2025 was $491.72M, a 11.86% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2024 was $557.87M, a 15.77% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2023 was $481.87M, a 6.75% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2022 was $451.42M, a 59.70% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $107.60M 10-Q · filed 2026-08-05 | $216.55M 10-Q · filed 2026-08-05 | $344.85M derived: sum of 3 quarters · filed 2026-08-05 | $436.74M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $108.95M 10-Q · filed 2026-05-06 | $237.25M derived: sum of 2 quarters · filed 2026-05-06 | $329.14M derived: sum of 3 quarters · filed 2026-05-06 | $467.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $128.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $220.19M derived: sum of 2 quarters · filed 2026-03-02 | $358.09M derived: sum of 3 quarters · filed 2026-08-05 | $491.72M 10-K · filed 2026-03-02 |
| 2025-09-30 | $91.89M 10-Q · filed 2025-11-06 | $229.79M derived: sum of 2 quarters · filed 2026-08-05 | $363.42M 10-Q · filed 2025-11-06 | $527.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $137.90M 10-Q · filed 2026-08-05 | $271.53M 10-Q · filed 2026-08-05 | $435.40M derived: sum of 3 quarters · filed 2026-08-05 | $563.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $133.63M 10-Q · filed 2026-05-06 | $297.50M derived: sum of 2 quarters · filed 2026-05-06 | $425.70M derived: sum of 3 quarters · filed 2026-05-06 | $564.50M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $163.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $292.07M derived: sum of 2 quarters · filed 2026-03-02 | $430.87M derived: sum of 3 quarters · filed 2026-03-02 | $557.87M 10-K · filed 2026-03-02 |
| 2024-09-30 | $128.20M 10-Q · filed 2025-11-06 | $267.00M derived: sum of 2 quarters · filed 2025-11-06 | $394.00M 10-Q · filed 2025-11-06 | $525.70M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $138.80M 10-Q · filed 2025-08-06 | $265.80M 10-Q · filed 2025-08-06 | $397.50M derived: sum of 3 quarters · filed 2026-03-02 | $518.39M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $127.00M 10-Q · filed 2025-05-06 | $258.70M derived: sum of 2 quarters · filed 2026-03-02 | $379.60M derived: sum of 3 quarters · filed 2026-03-02 | $498.16M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $131.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $252.59M derived: sum of 2 quarters · filed 2026-03-02 | $371.16M derived: sum of 3 quarters · filed 2026-03-02 | $481.87M 10-K · filed 2026-03-02 |
| 2023-09-30 | $120.89M 10-Q · filed 2024-11-06 | $239.46M derived: sum of 2 quarters · filed 2024-11-06 | $350.17M 10-Q · filed 2024-11-06 | $470.65M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $118.56M 10-Q · filed 2024-08-07 | $229.28M 10-Q · filed 2024-08-07 | $349.76M derived: sum of 3 quarters · filed 2025-02-28 | $454.54M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $110.71M 10-Q · filed 2024-05-01 | $231.19M derived: sum of 2 quarters · filed 2025-02-28 | $335.98M derived: sum of 3 quarters · filed 2025-02-28 | $490.30M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $120.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $225.26M derived: sum of 2 quarters · filed 2025-02-28 | $379.58M derived: sum of 3 quarters · filed 2025-02-28 | $451.42M 10-K · filed 2025-02-28 |
| 2022-09-30 | $104.79M 10-Q · filed 2023-11-01 | $259.10M derived: sum of 2 quarters · filed 2023-11-01 | $330.94M 10-Q · filed 2023-11-01 | $409.00M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $154.32M 10-Q · filed 2023-08-02 | $226.16M 10-Q · filed 2023-08-02 | $304.21M derived: sum of 3 quarters · filed 2024-02-28 | $365.34M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $71.84M 10-Q · filed 2023-05-02 | $149.90M derived: sum of 2 quarters · filed 2024-02-28 | $211.02M derived: sum of 3 quarters · filed 2024-02-28 | $283.37M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $78.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $139.18M derived: sum of 2 quarters · filed 2024-02-28 | $211.53M derived: sum of 3 quarters · filed 2024-02-28 | $282.66M 10-K · filed 2024-02-28 |
| 2021-09-30 | $61.13M 10-Q · filed 2022-11-02 | $133.47M derived: sum of 2 quarters · filed 2022-11-02 | $204.60M 10-Q · filed 2022-11-02 | $290.65M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $72.35M 10-Q · filed 2022-08-02 | $143.48M 10-Q · filed 2022-08-02 | $229.52M derived: sum of 3 quarters · filed 2022-08-02 | $304.90M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $71.13M 10-Q · filed 2022-05-04 | $157.18M derived: sum of 2 quarters · filed 2022-05-04 | $232.55M derived: sum of 3 quarters · filed 2022-05-04 | $306.24M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $86.05M 10-K · filed 2021-03-01 | $161.42M derived: sum of 2 quarters · filed 2021-11-03 | $235.11M derived: sum of 3 quarters · filed 2021-11-03 | $317.88M 10-K · filed 2023-02-28 |
| 2020-09-30 | $75.37M 10-Q · filed 2021-11-03 | $149.06M derived: sum of 2 quarters · filed 2021-11-03 | $231.83M 10-Q · filed 2021-11-03 | $313.25M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $73.69M 10-Q · filed 2021-08-04 | $156.46M 10-Q · filed 2021-08-04 | $237.88M derived: sum of 3 quarters · filed 2021-08-04 | $313.31M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $82.77M 10-Q · filed 2021-05-05 | $164.19M derived: sum of 2 quarters · filed 2021-05-05 | $239.62M derived: sum of 3 quarters · filed 2021-05-05 | $307.01M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $81.42M 10-K · filed 2021-03-01 | $156.85M derived: sum of 2 quarters · filed 2021-03-01 | $224.25M derived: sum of 3 quarters · filed 2021-03-01 | $284.81M 10-K · filed 2022-03-01 |
| 2019-09-30 | $75.43M 10-K · filed 2021-03-01 | $142.82M derived: sum of 2 quarters · filed 2021-03-01 | $203.39M 10-Q · filed 2020-11-05 | $267.61M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $67.39M 10-K · filed 2021-03-01 | $127.96M 10-Q · filed 2020-08-05 | $192.18M derived: sum of 3 quarters · filed 2021-03-01 | $245.22M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $60.57M 10-K · filed 2021-03-01 | $124.79M derived: sum of 2 quarters · filed 2021-03-01 | $177.83M derived: sum of 3 quarters · filed 2021-03-01 | $224.99M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $64.22M 10-K · filed 2020-02-26 | $117.26M derived: sum of 2 quarters · filed 2020-02-26 | $164.42M derived: sum of 3 quarters · filed 2020-02-26 | $207.76M 10-K · filed 2021-03-01 |
| 2018-09-30 | $53.04M 10-K · filed 2020-02-26 | $100.20M derived: sum of 2 quarters · filed 2020-02-26 | $143.54M 10-Q · filed 2019-11-07 | $175.76M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $47.16M 10-K · filed 2020-02-26 | $90.50M 10-Q · filed 2019-08-07 | $122.72M derived: sum of 3 quarters · filed 2020-02-26 | $150.89M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $43.34M 10-K · filed 2020-02-26 | $75.56M derived: sum of 2 quarters · filed 2020-02-26 | $103.74M derived: sum of 3 quarters · filed 2020-02-26 | $139.81M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $32.22M 10-K · filed 2019-02-28 | $60.40M derived: sum of 2 quarters · filed 2019-02-28 | $96.47M derived: sum of 3 quarters · filed 2019-02-28 | $122.68M 10-K · filed 2020-02-26 |
| 2017-09-30 | $28.18M 10-K · filed 2019-02-28 | $64.25M derived: sum of 2 quarters · filed 2019-02-28 | $90.46M 10-Q · filed 2018-10-31 | $113.40M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $36.07M 10-K · filed 2019-02-28 | $62.28M 10-Q · filed 2018-08-08 | $85.22M derived: sum of 3 quarters · filed 2019-02-28 | $107.41M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $26.22M 10-K · filed 2019-02-28 | $49.15M derived: sum of 2 quarters · filed 2019-02-28 | $71.34M derived: sum of 3 quarters · filed 2019-02-28 | $89.09M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $22.94M 10-K · filed 2018-03-01 | $45.12M derived: sum of 2 quarters · filed 2018-03-01 | $62.87M derived: sum of 3 quarters · filed 2018-03-01 | $83.75M 10-K · filed 2019-02-28 |
| 2016-09-30 | $22.18M 10-K · filed 2018-03-01 | $39.94M derived: sum of 2 quarters · filed 2018-03-01 | $60.81M 10-Q · filed 2017-11-01 | $85.14M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $17.75M 10-K · filed 2018-03-01 | $38.63M 10-Q · filed 2017-08-03 | $62.96M derived: sum of 3 quarters · filed 2018-03-01 | $78.05M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $20.88M 10-K · filed 2018-03-01 | $45.20M derived: sum of 2 quarters · filed 2018-03-01 | $60.30M derived: sum of 3 quarters · filed 2018-03-01 | $73.22M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $24.33M 10-K · filed 2017-02-28 | $39.42M derived: sum of 2 quarters · filed 2017-02-28 | $52.35M derived: sum of 3 quarters · filed 2017-02-28 | $75.04M 10-K · filed 2018-03-01 |
| 2015-09-30 | $15.09M 10-K · filed 2017-02-28 | $28.02M derived: sum of 2 quarters · filed 2017-02-28 | $50.71M derived: sum of 3 quarters · filed 2017-02-28 | |
| 2015-06-30 | $12.93M 10-K · filed 2017-02-28 | $35.62M derived: sum of 2 quarters · filed 2017-02-28 | ||
| 2015-03-31 | $22.70M 10-K · filed 2017-02-28 | |||
| 2014-12-31 | $49.31M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |